Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Trastuzumab and cardiotoxicity – is global longitudinal strain better?
Session:
CO 08 - Ecocardiografia
Speaker:
Nuno Craveiro
Congress:
CPC 2018
Topic:
B. Imaging
Theme:
03. Imaging
Subtheme:
03.1 Echocardiography
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Nuno Craveiro; Maria João Matos Vieira; Mariana Saraiva; Kevin Domingues; Beatriz Saldanha Santos; João Cotrim; Miguel Faria Alves; Marisa Peres; Margarida Leal
Abstract
<p>Background: Therapy for breast cancer is associated with cardiotoxicity (CT) mainly after treatment with antraciclines and trastuzumab. Left ventricular (LV) systolic impairment is a surrugate marker for cardiotoxicity and echocardiography evaluation with LV Ejection fraction (LVEF) and LV global longitudinal strain (GLS) can identify assyntomatic LV dysfunction.</p> <p>Methods: Retrospective review of 73 HER2+ cancer patients receiving trastuzumab theraphy from January 2015 to December 2017. Serial echocardiography with baseline echocardiogram and follow up studies every 12 weeks were analysed to evaluate LVEF and GLS. Cardiotoxicity was defined by a decrease in LVEF of 10% to a value < 53% or a GLS relative percentage reduction >15% from baseline.</p> <p>Results: Mean age was 60±12.4 years, mean BMI 25,5±5.3 kg/m2. Hipertension was a morbidity in 45% patients, diabetes mellitus in 12,3% and dyslipidemia in 27,4 %. Mean LVEF and GLS at baseline were 60,2±7 % and -20±2,5 %. Eighty-two percent of patients recieved treatment with anthracyclines and 60,3% radiotherapy, all of them were treated with trastuzumab. 345 echocardiograms were preformed (mean 4,73 per patient) and mean time follow-up was 443 days. During follow up 20 patients (27,4%) met criteria for cardiotoxicity: LVEF + GLS criterion were present in 5 (25%) patients, in 1 patient (5%) only LVEF identifyed CT and in 14 patients (70%) only GLS criteria fot CT was present. At follow up GLS was a better identifier of cardiotoxicity after one year (5th evaluation GLS -20±1,9 % vs -16,2±2 %, p=0,002).</p> <p>Conclusion: Assyntomatic LV disfunction occured in 27,4% of patients undergouing HER2+ cancer therapy with trastuzumab. Cumulative effects of chemotherapy, radiotheraphy and direct transtuzumab cardiotoxicity may explain this high rate of CT as assessed by echocardiography. GLS may be a more sensitive parameter to detect cardiotoxicity at follow-up.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site